Stifel lowered the firm’s price target on Tesla (TSLA) to $474 from $492 and keeps a Buy rating on the shares. The firm cites the company’s “mixed” Q4 results, uncertainty caused by the ...

Good day and welcome to the Stifel Financial fourth quarter financial results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr ...

(RTTNews) - Stifel Financial Corp. (SF) revealed earnings for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings totaled $234.69 million ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Stifel Financial Corp. announced a cash dividend of $0.46 per share on its common stock, payable on March 17, 2025, to shareholders recorded by March 3, 2025. Additionally, the company declared ...

Stifel Financial (SF) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $1.97 per share. This compares to earnings of $1.50 per share a year ago.

On Wednesday, Stifel analysts revised their price target for FTAI Aviation (NASDAQ:FTAI) shares, lowering it significantly to $100 from the previous target of $167, while still retaining a Buy ...

Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp., according to people familiar with the matter. The partnership at ...

https://www.tipranks.com/news/the-fly/johnson-controls-price-target-raised-to-93-from-86-at-rbc-capital Stifel lowered the firm’s price target on Fastenal (FAST) to ...

On January 31, Stifel reduced Intel’s price target from $25 to $21 while maintaining a Hold rating. The firm noted that although Q4 results exceeded expectations, Q1 guidance fell short.

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...